Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease
Journal of Clinical Medicine · 21.07.2023 · 12 (14) · 4821
DOI: 10.3390/jcm12144821 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.07.2023. Verfasst von Shu Xian Loh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, British Heart Foundation and Heart Research UK.
Abstract (Originalsprache)
Acute myocardial infarction (MI) is the most common and dramatic complication of atherosclerosis, which, despite successful reperfusion therapy, can lead to incident heart failure (HF). HF occurs when the healing process is impaired due to adverse left ventricular remodelling, and can be the result of so-called ischaemia/reperfusion injury (IRI), visualised by the development of intramyocardial haemorrhage (IMH) or microvascular obstruction (MVO) in cardiac MRI. Thus far, translation of novel pharmacological strategies from preclinical studies to target either IRI or HF post MI have been largely unsuccessful. Anti-inflammatory therapies also carry the risk of affecting the immune system. Fractalkine (FKN, CX3CL1) is a unique chemokine, present as a transmembrane protein on the endothelium, or following cleavage as a soluble ligand, attracting leukocyte subsets expressing the corresponding receptor CX3CR1. We have shown previously that the fractalkine receptor CX3CR1 is associated with MVO in patients undergoing primary PCI. Moreover, inhibition of CX3CR1 with an allosteric small molecule antagonist (KAND567) in the rat MI model reduces acute infarct size, inflammation, and IMH. Here we review the cellular biology of fractalkine and its receptor, along with ongoing studies that introduce CX3CR1 as a future target in coronary artery disease, specifically in patients with myocardial infarction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.
- Translational Research Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
- Academic Cardiovascular Unit, The James Cook University Hospital, Middlesbrough TS4 3BW, UK.
- Population Health Science Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
- Kancera AB, Karolinska Institutet Science Park, 171 65 Solna, Sweden.
- Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
ORCID-Profile: Shu Xian Loh, Yasemin Ekinci, David Austin, Ioakim Spyridopoulos
Förderung
- British Heart Foundation
- British Heart Foundation and Heart Research UK
Zitieren
APA
Loh, S. X., Ekinci, Y., Spray, L., Jeyalan, V., Olin, T., Richardson, G., Austin, D., Alkhalil, M., & Spyridopoulos, I. (2023). Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease. Journal of Clinical Medicine, 12(14), 4821. https://doi.org/10.3390/jcm12144821
Vancouver
Loh SX, Ekinci Y, Spray L, Jeyalan V, Olin T, Richardson G, et al. Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease. Journal of Clinical Medicine. 2023;12(14):4821. doi:10.3390/jcm12144821
BibTeX
@article{Loh2023,
author = {Loh, Shu Xian and Ekinci, Yasemin and Spray, Luke and Jeyalan, Visvesh and Olin, Thomas and Richardson, Gavin and Austin, David and Alkhalil, Mohammad and Spyridopoulos, Ioakim},
title = {Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {14},
pages = {4821},
doi = {10.3390/jcm12144821}
}
EUVIMED